Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade

HLA Class I Molecules Regulate IFN-  Production Induced in NK Cells by Target Cells, Viral Products, or Immature Dendritic Cells through the Inhibitory Receptor ILT2/CD85j

(2014) E. Morel et al.   JOURNAL OF IMMUNOLOGY

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

(2014) Anne-Sophie Chretien et al.   Frontiers in Immunology

At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity

(2013) Anne Danielou-Lazareth et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages

(2013) Giulia Fregni et al.   PLoS One

Monitoring NK cell activity in patients with hematological malignancies

(2013) Sébastien Viel et al.   OncoImmunology

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

(2012) María P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients

(2012) Yamila S Rocca et al.   Innate Immunity

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

(2011) M. P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications

(2011) Estrella Mariel Levy et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Human NK cells display major phenotypic and functional changes over the life span

(2010) Magali Le Garff-Tavernier et al.   AGING CELL

Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes

(2010) Julie A. Y. Billar et al.   ANNALS OF SURGICAL ONCOLOGY

The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer

(2010) E. M. de Kruijf et al.   CLINICAL CANCER RESEARCH

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients

(2009) Md. Zahidunnabi Dewan et al.   BIOMEDICINE & PHARMACOTHERAPY

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

T cell subset-specific susceptibility to aging

(2008) Marta Czesnikiewicz-Guzik et al.   CLINICAL IMMUNOLOGY

Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells

(2008) Nathalie T. Joncker et al.   IMMUNOLOGICAL REVIEWS

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE